Global Blood Therapeutics, Inc. (NASDAQ:GBT) Files An 8-K Other EventsItem 8.01. Other Events.
On October 24, 2017, Global Blood Therapeutics, Inc. issued a press release announcing that the World Health Organization and the United States Adopted Name Council have each approved “voxelotor” as the International Nonproprietary Name and USAN, respectively, for its lead product candidate GBT440 (the “Press Release”). A copy of the Press Release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description |
| 99.1 | Press Release, dated October 24, 2017 |
Global Blood Therapeutics, Inc. ExhibitEX-99.1 2 exh_991.htm PRESS RELEASE EdgarFilingEXHIBIT 99.1Global Blood Therapeutics Announces Approval of First-in-Class “Voxelotor” as Nonproprietary Name for GBT440 SOUTH SAN FRANCISCO,…To view the full exhibit click here
About Global Blood Therapeutics, Inc. (NASDAQ:GBT)
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company’s segment is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. It is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD) and is evaluating GBT440 in SCD subjects in an ongoing Phase I/II clinical trial. SCD is a genetic disease marked by red blood cell (RBC) destruction and occluded blood flow and hypoxia, leading to anemia, stroke, multi-organ failure, severe pain crises, and shortened patient life span. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. It is also engaged in other research and development activities targeted towards hereditary angioedema (HAE).